City reacts negatively as GlaxoSmithKline announces plans for new drugs

doi:10.1136/bmj.327.7428.1366

BMJ 2003;327:1366 (13 December), doi:10.1136/bmj.327.7428.1366

News roundup

City reacts negatively as GlaxoSmithKline announces plans for new drugs

London Owen Dyer

Europe�s biggest drug company, GlaxoSmithKline (GSK), saw its share price fall last week, despite unveiling details of its "product pipeline" for the next five years.

GSK�s chief executive, Jean-Pierre Garnier, told London market analysts: "There is no doubt that after 2006, GSK will outpace the rest of the industry." But investors saw little prospect of immediate gain, with most of the new drugs years away from possible approval with regulatory hurdles still to overcome.

This week�s newspapers suggested that GSK had shot itself in the foot when its vice president of genetic research, Allen Roses, told a scientific meeting in London that the "vast majority of drugs only work in 30 or 50% of people." It was reported on the front page of the Independent newspaper on 8 December .

But Navid Malik, analyst at Williams de Broë, said this was not news to institutional investors. "Other . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?